a mix of legacy drug makers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus covid 19 which was first detected in december in wuhan china has since sickened nearly 4 6 million people worldwide and killed more than 300 000 as of mid may the food and drug administration has issued two emergency use authorizations for covid 19 treatments including one for hydroxychloroquine sulfate and chloroquine phosphate in march to treat covid 19 patients and one for gilead sciences inc s remdesivir on may 1 no drugs or vaccines have received fda approval read more of marketwatch s coverage of covid 19 in the u s many of the publicly traded companies that are initiating development have received funding from two organizations the biomedical advanced research and development authority or barda which is a division of the department of health and human services and the national institute of allergy and infectious diseases or niaid a division of the national institutes of health some companies have also received funding from coalition for epidemic preparedness innovations or cepi a global organization based in oslo that has provided millions of dollars in funding to vaccine makers other companies are funding trials by themselves or through life sciences company partnerships these are some of the companies developing treatments or vaccines in the u s for covid 19 as of early may an earlier version of the article included several adjuvant platform technologies that are used to aid the development process and a privately held company but they have since been removed to focus on public companies type antibody treatment stage preclinical background the very early stage collaboration between amgen inc amgn 0 71 and adaptive biotechnologies corp adpt 3 93 seeks to discover antibodies that can be used to prevent or treat covid 19 financial terms of the exclusive collaboration will be completed in the coming weeks the companies said april 2 there may well be more than one generation of antibody therapeutics entering the clinic amgen r d evp david reese told investors on an earnings call also in the works amgen will test otezla as a covid 19 therapy treating respiratory distress in late stage patients with the company saying april 30 that it plans to put the oral psoriasis drug into trials in the coming weeks year to date stock performance amgen s stock is down 1 9 adaptive s is up 10 3 type vaccine stage preclinical name adcovid background altimmune inc alt 34 74 said march 30 it is partnering with university of alabama at birmingham to develop a single dose intranasal covid 19 vaccine they said they plan to put the vaccine candidate into phase 1 trials in the third quarter the preclinical company is also developing vaccines for anthrax and the flu year to date stock performance shares of altimmune have gone up 60 8 type mrna vaccine stage phase 1 2 name bnt162 program background pfizer inc pfe 0 70 announced march 17 it would help develop and distribute biontech se s bntx 1 41 covid 19 vaccine candidate though the deal excludes china the 360 patients in the u s trial had started to receive the first doses of the four vaccine candidates included in the study as of may 5 dosing in 200 participants in the german trial began april 23 as part of the deal pfizer will pay 185 million upfront with additional possible future milestone payments of up to 563 million mikael dolsten pfizer s chief scientific officer said during an april 28 earnings call that the companies expect the first round of trial data in may or june with the vaccine candidate moving into expanded trials that could allow emergency use or accelerated approval coming in the fall possibly october biontech is also testing the vaccine in collaboration with shanghai fosun pharmaceutical group co ltd in china pfizer and biontech for several years have said they are working on mrna based influenza vaccines year to date stock performances shares of biontech have soared 47 6 pfizer s stock is down 1 7 type treatment stage phase 2 and phase 2b 3 clinical trials name leronlimab background cytodyn inc cydy 1 29 a preclinical biotechnology company based in vancouver is testing its experimental drug leronlimab in two types of covid 19 patients the investigational therapy hasn t been approved for any indications for covid 19 it is being proposed as a treatment for mild to moderate respiratory complications that occur in patients with the disease as well as severely and critically ill patients the randomized double blind placebo controlled study will test the efficacy and safety of leronlimab in 75 patients cytodyn had been studying the experimental therapy as a treatment for people with hiv and a form of metastatic breast cancer year to date stock performance cytodyn s stock has soared 213 0 type treatment stage emergency use authorization name remdesivir background gilead sciences inc gild 0 77 is a longtime drugmaker best known for developing the first major cure for hepatitis c in sovaldi a therapy that changed the standard of care for that disease but also kicked off the national debate about drug pricing the company has experience developing and marketing hiv drugs including truvada for pre exposure prophylaxis prep its preventive hiv medicine it received an emergency use authorization from the food and drug administration in the u s on may 1 based on preliminary results from two clinical trials one conducted by the niaid and one by gilead in the niaid trial covid 19 patients taking the drug had a median recovery time of 11 days compared with 15 days for those patients taking placebo niaid director dr anthony fauci has said the drug is now considered the standard of care however other experts have had mixed responses to the data dr eric topol director of the scripps research translational institute said he thinks the drug is effective based on the preliminary data that has been made public it s just not that potent he said via email the drug was also used in two randomized controlled clinical trials in china results from one trial which was stopped early found the drug didn t produce statistically significant clinical benefits according to findings published in the lancet gilead in late march had to halt individual compassionate use requests for remdesivir as outbreaks worsened in the u s having provided the investigational therapy to 1 000 patients the system cannot support and process the overwhelming number of applications we have seen with covid 19 gilead ceo daniel o day said march 28 the company told investors on may 1 it may spend up to 1 billion this year to develop and manufacture remdesivir and it aims to have 500 000 treatment courses by october and 1 million by the end of 2020 gilead s notable clinical trials 1 the national institute of allergy and infectious diseases trial has enrolled patients in a randomized double blind placebo controlled phase 3 trial evaluating 1 063 hospitalized patients with covid 19 at 68 sites worldwide including at three sites in singapore and south korea according to the niaid however the majority of the study locations are in the u s the study began feb 21 and is expected to conclude april 1 2023 preliminary results from this trial were used to inform the eua 2 a gilead sponsored randomized open label phase 3 trial is testing remdesivir in 1 600 patients with moderate covid 19 it previously said it would enroll 600 participants the trial started enrolling patients in march with results to come in may the clinical trial listing states the study is taking place in 13 countries including hong kong singapore south korea and the u s 3 a gilead sponsored randomized open label phase 3 trial is evaluating remdesivir in 6 000 patients with severe covid 19 the drugmaker previously said it planned to include 400 participants in the trial the trial started enrolling patients in march and early results based on 397 patients included in the initial phase of the study were used to inform the eua the clinical trial listing states the study is taking place in hong kong singapore south korea and the u s results the eua followed two weeks of clinical trial data leaks that sent the company s stock soaring or tumbling depending on the news stat news reported april 16 that university of chicago medicine researchers saw rapid recoveries in 125 covid 19 patients remdesivir though that data isn t part of the full clinical trial data set a week later stat and the financial times reported that a draft of the clinical trial results for remdesivir showed that the drug didn t speed up improvement in patients in china or prevent them from dying the summary was reportedly published by accident on the world health organization s who website and then taken down what s next the drugmaker plans to donate 1 5 million vials about 140 000 10 day courses of treatment of the drug through june it also said may 5 that it plans to contract with pharmaceutical manufacturers abroad to ensure access to remdesivir outside of the u s the institute for clinical and economic review a group that assesses the cost effectiveness of medicines said gilead would need to charge 10 for a course of treatment to recoup its costs but could be priced as high as 4 500 per course of treatment to be considered effective year to date stock performance shares of gilead are up 21 2 type vaccine treatment name as03 adjuvant system for vaccines background glaxosmithkline gsk 0 22 is another leading vaccine maker having brought to market vaccines for human papillomavirus hpv and the seasonal flu among others it has announced a string of wide reaching collaborations during the pandemic most notably a deal with sanofi to jointly develop a vaccine candidate sanofi is also working with barda on a separate vaccine program as part of this agreement sanofi s s protein covid 19 antigen will be paired with glaxosmithkline s adjuvant technology the companies expect to launch clinical trials in the second half of the year terms of the agreement are expected to be completed this month also in the works gsk said feb 3 that the cepi funded university of queensland will have access to its vaccine adjuvant platform technology which is believed to both strengthen the response of a vaccine and limit the amount of vaccine needed per dose a separate deal with clover biopharmaceuticals inc a chinese biotechnology company which was announced in february is also using its adjuvant technology in combination with its vaccine candidate covid 19 s trimer in preclinical studies dr thomas breuer chief medical officer for gsk vaccines is leading work on vaccines and the adjuvant platform separately gsk and vir biotechnology inc announced a deal in early april in which gsk made a 250 million equity investment in vir as the two companies work together to develop two of vir s experimental therapies vir 7831 and vir 7832 expected to go to phase 2 clinical trials sometime in 2020 year to date stock performance shares of gsk have tumbled 11 3 type vaccine stage preclinical background heat biologics inc htbx 22 01 has previously announced that it is developing a vaccine for the novel coronavirus with the university of miami miller school of medicine it disclosed march 17 in a financial filing that its covid 19 vaccine candidate had been added to the world health organization s draft landscape of 41 candidate vaccines we are finalizing completion of the vaccine and plan to commence preclinical testing this quarter heat ceo jeff wolf said in an april 29 statement the company also recently joined the alliance for biosecurity which may help it secure government funding to support its rapid development production and distribution of its covid 19 vaccine according to maxim group analysts year to date stock performance heat s stock has gained 14 8 type dna based vaccine timeline phase 1 clinical trial name ino 4800 background another cepi grantee with roughly 17 million in total awards inovio pharmaceuticals inc ino 3 48 is testing its vaccine candidate in a phase 1 clinical trial at two sites in the u s the perelman school of medicine at the university of pennsylvania and the center for pharmaceutical research in kansas city mo inovio develops immunotherapies and vaccines but hasn t yet had a product approved for treatment for ino 4800 preclinical testing was performed between jan 23 and feb 29 the company began clinical trials in the u s with up to 40 participants in april dosing the first patient on april 6 inovio said it expects to have the first results from the trial in the fall and to have 1 million doses of the vaccine ready for additional clinical trials or emergency use by the end of the year inovio on march 12 announced a 5 million grant from the bill melinda gates foundation to test a delivery device for its vaccine candidate in late march inovio said that ology bioservices inc a contract development and manufacturing organization had received a 11 9 million contract from the department of defense to support future potential manufacturing of inovio s vaccine candidate for military personnel year to date stock performance shares of inovio have soared 209 5 type vaccine stage preclinical background johnson johnson jnj 1 03 announced feb 11 that it was working with barda to test its vaccine candidate with each party providing 1 billion for research and development and the public health organization funding the phase 1 trials we are also in discussions with other partners that if we have a vaccine candidate with potential we aim to make it accessible to china and other parts of the world dr paul stoffels j j s chief scientific officer said in a statement on march 13 j j said it started preclinical testing on multiple candidates in collaboration with beth israel deaconess medical center in boston and by march 30 it had identified a lead vaccine candidate the company said it is scaling up its vaccine manufacturing capabilities in the u s and abroad as part of its commitment to bring an affordable vaccine to the public on a not for profit basis for emergency pandemic use the company aims to put its lead vaccine candidate in a phase 1 clinical trial in september the company said march 30 and it may have investigational doses of the vaccine available by early 2021 for emergency use also in the works j j said in february that it had partnered with barda on a project that aims to screen existing antiviral medications including experimental or approved therapies that may be effective against covid 19 similar to gsk j j s advac and per c6 technologies are used to improve the development process for a vaccine and were also used to develop j j s experimental ebola vaccine year to date stock performance shares of j j are up 2 6 type rna based vaccine stage phase 1 name mrna 1273 background moderna inc mrna 9 89 received funding from cepi in january to develop an mrna vaccine against covid 19 on feb 24 it said it had shipped the first batch of mrna 1273 to the niaid for a phase 1 clinical trial in the u s clinical trials the first patient in the phase 1 trial received a dose of the vaccine candidate on march 16 the study is expected to enroll 45 healthy adult patients between the ages of 18 and 55 years old in an open label phase i clinical trial to test mrna 1273 as a vaccine for covid 19 participants will be followed for one year the trial which is expected to conclude june 1 2021 will be conducted at kaiser permanente washington health research institute in seattle cepi funded the manufacturing of the investigational vaccine for the first phase of the trial which is evaluating different doses for safety and immune response a phase 2 trial is expected to begin in the second quarter in mid april moderna said it will receive up to 483 million in barda funding to support its vaccine development program we believe that we would be able to supply millions of doses a month in 2020 and with further investments tens of millions a month in 2021 if the vaccine candidate is successful in the clinic moderna ceo st phane bancel said at the time year to date stock performance moderna s shares have gained 146 8 type vaccine stage phase 1 clinical trial name nvx cov2373 background novavax inc nvax 13 59 a preclinical biotechnology company announced feb 26 that it had several vaccine candidates in preclinical animal studies by april 8 the company said it had identified a covid 19 vaccine candidate and it plans to initiate a phase i clinical study in mid may the first phase of the placebo controlled study will enroll 130 healthy adults the first round of data from that study is expected in july in march the company said it had received 4 million from cepi to develop a covid 19 vaccine and that emergent biosolutions inc would support contract development and manufacturing for the experimental vaccine year to date stock performance its stock has gained 334 4 type prevention and treatment stage preclinical name regn cov2 background on feb 4 regeneron pharmaceuticals inc regn 4 52 announced it is working on developing monoclonal antibodies as treatments for covid 19 and during a may 5 earnings call it disclosed the name of the treatment regn cov2 the company s velocimmune platform uses genetically engineered mice with humanized immune systems in preclinical testing we are aiming to have hundreds of thousands of prophylactic doses ready for human testing by end of august a spokesperson said christos kyratsous vice president of infectious disease r d and viral vector technology is running the project clinical trials are expected to begin in june year to date stock performance regeneron s shares are up 37 0 type treatment stage phase 2 3 clinical trial name kevzara background the fda approved kevzara a treatment developed by regeneron and sanofi sny 0 45 as a therapy for rheumatoid arthritis in 2017 as part of a recently concluded longstanding r d partnership between the two companies clinical trials regeneron and sanofi said march 16 they had started a phase 2 3 trial testing kevzara as a treatment for patients who have been hospitalized with severe covid 19 infections this randomized double blind placebo controlled trial is expected to enroll up to 400 patients and will take place at 16 sites in the u s new york s mount sinai hospital the first site has started enrolling patients according to a company spokesperson the aim is to evaluate if the drug lessens patient fevers and their need for supplemental oxygen the phase 3 trial will evaluate if kevzara prevents deaths and reduces need for mechanical ventilation supplemental oxygen or hospitalization early results from a small 21 person trial in china that haven t been peer reviewed found that some patients who were taking a similar drug roche holdings actemra reported reductions in fever and 7 of them had a reduced need for supplemental oxygen within days of starting treatment results on march 30 the companies said the first patient in their global trial had been treated however in late april the companies said they would limit the phase 3 trial to only include patients defined as critical which includes those requiring mechanical ventilation high flow oxygenation or being cared for in an intensive care unit given that sicker patients seemed to show some improvement while taking the drug the next phase of the study will also only include a higher dose of the drug 400 milligrams and the placebo and not the lower dose of 200 milligrams used in the mid stage trial type treatment stage phase 3 clinical trial name actemra background roche holdings ag s rog 1 36 actemra was first approved in 2010 as a rheumatoid arthritis drug the swiss drugmaker has initiated a phase 3 clinical trial evaluating actemra as a treatment for patients with covid 19 who have been hospitalized with severe pneumonia roche began enrolling around 330 patients in early april at 55 sites in the u s and elsewhere in the world the company plans to examine patient mortality and need for mechanical ventilation or an intensive care unit stay among other primary and secondary endpoints on april 3 the first patients in the trial which is in partnership with barda were treated a roche spokesperson said by email results are expected in early summer the company said april 22 also in the works roche has developed a diagnostic and an antibody test for covid 19 both have received euas from the fda year to date stock performance roche s stock is down 1 3 type vaccines stage preclinical name no name yet background starting feb 18 sanofi is working with barda to test a preclinical vaccine candidate for severe acute respiratory syndrome sars for covid 19 using its recombinant dna platform a spokesperson said sanofi aims to put a vaccine into a phase 1 clinical trial between march 2021 and august 2021 it announced a separate program with translate bio inc tbio 3 71 on march 27 to develop a mrna vaccine the french drugmaker has a long history of producing vaccines in its sanofi pasteur business and acquired this candidate through its 2017 acquisition of protein sciences for 750 million it previously worked with the organization on flu vaccines scientists in meriden ct are working on the vaccine david loew sanofi pasteur s evp is leading the project year to date stock performance shares of sanofi are down 0 7 type antibody treatment stage preclinical name tak 888 background japanese drugmaker takeda pharmaceutical co ltd tak 2 36 4502 1 87 said march 4 that it plans to test hyperimmune globulins for people who are at high risk for infection as part of its research which will be performed in georgia takeda said it would need access to plasma from people who have recovered from covid 19 or those who have received a vaccine if one is developed dr rajeev venkayya president of takeda s vaccine business is the co lead of the company s covid 19 response team in april takeda and csl behring cslly 5 81 said they formed an alliance to develop a plasma derived treatment for covid19 biotest ag and octapharma also joined the alliance also in the works like j j takeda plans to examine whether other therapies both experimental or with regulatory approval may have treatment potential year to date stock performance shares of takeda are down 10 0 type vaccine stage preclinical background vaxart inc vxrt 4 81 was one of the first companies to announce plans to develop a vaccine when it did so jan 31 in march the clinical stage company announced that emergent biosolutions will help develop and manufacture its oral vaccine candidate we believe an oral vaccine administered using a room temperature stable tablet may offer enormous logistical advantages in the rollout of a large vaccination campaign vaxart ceo wouter latour said in a march 18 news release the company plans to start a phase 1 clinical trial in the u s in the second half of 2020 a company executive said as of march 31 it has five vaccine candidates for preclinical testing year to date stock performance vaxart s stock is up 621 8 type treatments stage preclinical name vir 2703 also called aln cov vir 7831 and vir 7832 background vir biotechnology inc vir 1 21 has two preclinical treatment candidates vir 7831 and vir 7832 and on may 4 said it had identified a treatment candidate as part of a partnership with alnylam pharmaceuticals inc alny 0 03 the companies said they aim to file for an investigational new drug application by the end of 2020 before the proposed inhaled treatment or prevention therapy would enter trials also in the works in many ways vir has been one of the most prolific partners in the biotech field during the pandemic the preclinical company is run by george scangos the former ceo of biogen inc biib 0 29 starting feb 25 it said it was collaborating with shanghai based wuxi biologics to test monoclonal antibodies as a treatment for covid 19 if the treatment is approved wuxi will commercialize it in china while vir will have marketing rights for the rest of the world it later announced a partnership with biogen to help develop and manufacture its monoclonal antibodies as a potential treatment for covid 19 biogen will handle clinical manufacturing of vir s antibodies the company said vir later announced a research agreement with generation bio as part of its covid 19 antibody development program most recently it announced the equity investment from gsk year to date stock performance vir shares have jumped 138 2 the world health organization said that it will temporarily drop hydroxychloroquine the malaria drug u s president trump has said he is taking from its global study into experimental covid 19 treatments saying that its experts need to review all available evidence to date copyright 2020 marketwatch inc all rights reserved by using this site you agree to the subscriber agreement terms of use updated 03 26 2020 privacy notice and cookie notice intraday data provided by factset and subject to terms of use historical and current end of day data provided by factset all quotes are in local exchange time real time last sale data for u s stock quotes reflect trades reported through nasdaq only intraday data delayed at least 15 minutes or per exchange requirements 